We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04809805
Recruitment Status : Recruiting
First Posted : March 22, 2021
Last Update Posted : September 21, 2022
Sponsor:
Information provided by (Responsible Party):
Bayer

Brief Summary:

Researchers are looking for a better way to treat people who have advanced cancer.

In this study researchers want to learn more about a new substance called BAY2666605. BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A. This complex drive cancer cells into cell death by a mechanism called apoptosis. The complex is only formed in the cancers which contain both proteins.

This study is done in adult patients who have certain types of advanced cancers that cannot be cured by drugs that are currently available. The cancer types include skin cancer that has spread to other parts of the body and cancer that started in the bones or soft tissue, the ovaries, or the brain. Patients with these cancers are only included if the cells of the patient's cancer contain the building plan to produce SLFN12-phosphodiesterase 3A (PDE3A) complex. To confirm this, a specific test is performed with the cancer cells.

The researchers will study how BAY2666605 moves into, through and out of the body. Researchers will try to find the best dose that can be given, how safe BAY2666605 is and how it affects the body. Researchers will also study the action of BAY2666605 against the cancer. Part A will include about 36 participants and up to another 12 participants. Part B will include about 41 participants. All of the participants will take BAY2666605 by mouth as either a liquid or as tablets.

During the study, the participants will take the treatment in 4 week periods called cycles. In each cycle, the participants will in general take BAY2666605 once daily. The participants may also be asked to do overnight fasting before the intake of substance and to have standard high-fat, high-calorie breakfast on some days before taking the dose.

These 4 week cycles will be repeated throughout the trial. The participants can take BAY2666605 until their cancer gets worse, until they have medical problems, or until they leave the trial. Participants will have around 18 visits in each cycle. Some of the visits can also be done via Phone.

During the trial, the study team will take blood and urine samples, do physical examinations and check the participants' heart health using an electrocardiogram (ECG) and an ultrasound of the heart. The study team will also take pictures of the participants' tumors using CT or MRI scans. The study team will ask how the participants are feeling, if participants have any medical problems or if participants are taking any other medicine. About 1 month and 3 months after the last dose, the participants will have another visit and a phone call respectively where participants will be checked for and asked about medical problems. The researchers will then contact the participants every 3 months until the trial ends.


Condition or disease Intervention/treatment Phase
Metastatic Melanoma and Other Solid Tumors Drug: BAY2666605 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 89 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open Label, Phase 1, First-in-human, Study to Evaluate Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of Schlafen12 Complex Inducer (SLFN12 ci) BAY 2666605 in Participants With Metastatic Melanoma and Other Advanced Solid Tumors.
Actual Study Start Date : April 15, 2021
Estimated Primary Completion Date : March 5, 2024
Estimated Study Completion Date : June 25, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Dose escalation of BAY2666605
Approximately 7 or 8 dose levels are planned.
Drug: BAY2666605
One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.

Experimental: Dose expansion of BAY2666605
Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
Drug: BAY2666605
One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.




Primary Outcome Measures :
  1. Incidence and severity of TEAEs including TESAEs [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    TEAEs: Treatment emergent adverse events; TESAEs:Treatment emergent serious adverse events

  2. The incidence of DLTs at each dose level in the Dose Escalation part of the study [ Time Frame: Up to 28 + 14 days ]
    DLT: Dose limiting toxicity

  3. Maximal plasma exposure (Cmax) of BAY2666605 [ Time Frame: Cycle 1 Day 1 ]
  4. AUC(0-24) of BAY2666605 [ Time Frame: Cycle 1, Day 1 ]
  5. RP2D of BAY2666605 [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    RP2D: Recommended phase 2 dose. RP2D will be defined in the expansion part.

  6. Cmax,md of BAY2666605 [ Time Frame: Cycle 1, Day 15 ]
  7. AUC(0-24)md of BAY2666605 [ Time Frame: Cycle 1, Day 15 ]

Secondary Outcome Measures :
  1. ORR [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    ORR: Objective response rate

  2. DCR [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    DCR: Disease control rate

  3. DOR [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    DOR: Duration of response

  4. PFS by investigator assessment [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    PFS: Progression-free survival

  5. OS [ Time Frame: Up to 6 months after the last participant's first study intervention or until the end of the study, whichever comes first. ]
    OS: Overall survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Pre-screening:

  • Signed informed consent for pre-screening
  • Male or female participants aged ≥ 18 years
  • Participants with histologically confirmed diagnosis of melanoma, glioblastoma/anaplastic astrocytoma, sarcoma or epithelial ovarian cancer/fallopian tube/primary peritoneal cancer
  • Availability of archival tumor tissue (5-10 for prescreening, further 20 to be provided at screening)
  • ECOG ≤2

Main Screening :

  • Positive SLFN12/PDE3A expression in archival tumour
  • Minimum life expectancy at least 12 weeks
  • Documented radiological disease progression after treatment with all available standard of care therapies for advanced/metastatic disease and at least one measurable lesion
  • Adequate bone marrow, liver, and renal function
  • Adequate blood clotting
  • Left ventricular ejection fraction >50%
  • All AEs due to previous therapies to CTCAE Grade ≤1. Grade ≤2 neuropathy, fatigue, alopecia, or anorexia, for which further resolution is not expected, may be eligible.
  • Negative pregnancy test and use of highly effective contraception
  • Signed informed consent for main screening

Exclusion Criteria:

Pre-screening:

  • Any malabsorption conditions
  • Known HIV infection, active HBV or HCV infection
  • Known hypersensitivity to PDE3 inhibitors, or excipients in the formulation; concomitant treatment with any other PDE3 inhibitors
  • Participants with clinically relevant cardiovascular diseases and/or relevant ECG findings
  • Participants with history of hemorrhage, bleeding disorders or platelet function abnormalities, aneurysm or aneurysmal vasculopathy; Participants with arterial thromboembolic events (ATEs) or venous thromboembolic events (VTEs), including transient ischemic attacks or pulmonary embolism within 6 months before the start of BAY 2666605 or deep vein thrombosis within 3 months before the start of BAY 2666605; Participant with a history of gastrointestinal (GI) ulcerations or perforation, fistula formation involving any internal organs.

Main screening

  • Moderate or severe hepatic impairment
  • History of organ allograft transplantation, including allogeneic bone marrow
  • Previous of co-existing cancer(s) distinct in primary site or histology from the cancer evaluated in this study (with few exceptions)
  • Participants with any history of primary meningeal tumors and/or Any active symptomatic or untreated central nervous system (CNS) metastases and/or a number of prior and concomitant therapies
  • Major surgery, significant trauma, serious non-healing wound, wound healing complications, ulcer or bone fracture within 4wks prior to 1st dose

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04809805


Contacts
Layout table for location contacts
Contact: Bayer Clinical Trials Contact (+)1-888-84 22937 clinical-trials-contact@bayer.com

Locations
Layout table for location information
United States, Connecticut
Yale University School of Medicine Not yet recruiting
New Haven, Connecticut, United States, 06510
United States, Massachusetts
Massachusetts General Hospital Suspended
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute Suspended
Boston, Massachusetts, United States, 02215-5450
Beth Israel Deaconess Medical Center Suspended
Boston, Massachusetts, United States, 02215
United States, Minnesota
Mayo Clinic - Rochester Withdrawn
Rochester, Minnesota, United States, 55905
United States, Pennsylvania
UPMC Hillman Cancer Center Not yet recruiting
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Sarah Cannon Development Innovations Recruiting
Nashville, Tennessee, United States, 37203
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
South Texas Accelerated Research Therapeutics, LLC Recruiting
San Antonio, Texas, United States, 78229-3307
Sponsors and Collaborators
Bayer
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT04809805    
Other Study ID Numbers: 20733
First Posted: March 22, 2021    Key Record Dates
Last Update Posted: September 21, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas